New investors include Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec's Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).
The funding will support the advancement of Schrödinger's wholly-owned drug discovery pipeline and enable continued expansion of the company's collaborations with biopharma companies worldwide.
These partnerships have already led to two FDA-approved oncology drugs, several clinical-stage assets, and more than two dozen additional programmes moving through discovery and development.
The investment will also support Schrödinger's ongoing research and development efforts to extend the reach of its proprietary technology platform, which integrates novel physics-based molecular simulations and machine learning to enable exploration of vastly more chemical space than is possible through traditional drug discovery methods.
This expanded and accelerated exploration opens new frontiers for discovery of novel compounds for both therapeutic indications and materials design.
Schrödinger has a global business, licensing its computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R and D in both drug discovery and materials design.
The company has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.
Schrödinger's investment in basic research continues to drive advances in its computational platform.
Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world.
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
Merck finalises acquisition of Harpoon Therapeutics Inc
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA
Camurus reports Oclaiz NDA accepted by FDA for acromegaly treatment
TME Pharma plans NOX-A12 Phase 2 trial in brain cancer after FDA IND clearance